Brian Szelc
Psychiatric/Mental Health · Neshannock, PANPI 1225451750
Payments from drug & device makers
Across 222 payments — averaging $24.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$884
- Teva Pharmaceuticals USA, Inc.$645
- Johnson & Johnson$593
- Otsuka America Pharmaceutical, Inc.$576
- Alkermes, Inc.$548
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$415
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,20897%
- Education$1443%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 38 | $884 |
| Teva Pharmaceuticals USA, Inc. | 28 | $645 |
| Johnson & Johnson | 16 | $593 |
| Otsuka America Pharmaceutical, Inc. | 26 | $576 |
| Alkermes, Inc. | 24 | $548 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 19 | $415 |
| Tris Pharma Inc | 6 | $313 |
| Lundbeck LLC | 16 | $278 |
| Neurocrine Biosciences, Inc. | 11 | $207 |
| Vanda Pharmaceuticals Inc. | 11 | $204 |
| Axsome Therapeutics, Inc. | 7 | $178 |
| E.r. Squibb & Sons, L.L.C. | 3 | $140 |
| Janssen Scientific Affairs, LLC | 1 | $80 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $46 |
| Collegium Pharmaceutical, Inc. | 2 | $43 |
| Acadia Pharmaceuticals Inc | 2 | $43 |
| Supernus Pharmaceuticals, Inc. | 2 | $37 |
| Neuronetics, Inc. | 1 | $32 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Noven Therapeutics, LLC | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Braeburn Inc. | 1 | $15 |
| Corium, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$336
- SPRAVATO$261
- Dyanavel XR$242
- Quillivant$242
- Quillichew ER$242
- COBENFY$115
How this compares
$5,352 in reported general payments places this provider in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
See all psychiatric/mental health providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $213,827 |
| Invega SustennaPaliperidone Palmitate | 39 | $113,152 |
| NuplazidPimavanserin Tartrate | 26 | $67,357 |
| FanaptIloperidone | 28 | $49,135 |
| VraylarCariprazine Hcl | 21 | $29,607 |
| Clozapine | 206 | $23,244 |
| AuvelityDextromethorphan Hbr/Bupropion | 17 | $18,701 |
| RexultiBrexpiprazole | 14 | $15,743 |
| Rivastigmine | 71 | $14,581 |
| RivastigmineRivastigmine Tartrate | 127 | $12,755 |
| NuedextaDextromethorphan Hbr/Quinidine | 15 | $9,597 |
| TrintellixVortioxetine Hydrobromide | 29 | $7,886 |
| Paliperidone ErPaliperidone | 17 | $6,090 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 13 | $5,554 |
| Divalproex Sodium | 125 | $5,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $207 | $213,82727 claims |
| Johnson & JohnsonInvega Sustenna | $593 | $113,15239 claims |
| Acadia Pharmaceuticals IncNuplazid | $43 | $67,35726 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $204 | $49,13528 claims |
| AbbVieVraylar | $884 | $29,60721 claims |
| Axsome Therapeutics, Inc.Auvelity | $178 | $18,70117 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $576 | $15,74314 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $15 | $9,59715 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $46 | $7,88629 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,041 psychiatric/mental health providers in Pennsylvania.
Other psychiatric/mental health in Neshannock
- Kimberly GarciaAllentown$573K
- Cortney SmithWashington$227K
- Britney KeplerPittsburgh$158K
- Kirstyn KamegBethel Park$136K
- Anna DipietroDowningtown$131K
- Deena MasciocchiLanghorne$71K
- Joseph GagnonChesterbrook$64K
- Michelle CohenWashington$62K
- Sharon KatzJenkintown$51K
- Jennifer BowmanCanonsburg$48K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.